Melanoma News & Features
Nivolumab and dabrafenib plus trametinib up survival in melanoma without, with BRAF, respectively.
There may be a correlation between tumor necrosis factor (TNF)-alpha inhibitors and the development of uveal melanoma.
Treatment with a combination of the drugs sargramostim plus ipilimumab, rather than ipilimumab alone, yielded longer overall survival and lower toxicity for patients with metastatic melanoma.
Pairing ipilimumab with sargramostim gives patients about five extra months survival time for patients with advanced melanoma, researchers report.
A gigapixel camera that takes high-resolution snapshots of the entire body could prove to be a new tool for whole-body skin cancer screening.
- Study investigating advanced MRI scans to detect prostate cancer set to begin
- TNF-alpha inhibitors associated with uveal melanoma
- Improved survival in pediatric umbilical cord transplants for hematologic cancers
- Most internet sites on prostate cancer disagree with expert panel's recommendations
- Radiation exposure linked to aggressive thyroid cancers
- A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia
- Early palliative care can cut hospital readmissions for cancer patients
- ONA Interview: Breaking the barriers to effective palliative care
- Fluorescent tattoos may improve self-esteem in patients receiving radiotherapy for breast cancer
- Cancer prehabilitation: One step toward improved outcomes
- Classifying gene mutations in neuroblastoma may point to improved treatments
- International study shows wide differences in 5-year survival rates across the globe
- Diagnostic grading system developed for cancer-related weight loss
- Overweight and obesity status causes nearly half a million new cancer cases each year
- Navigation and survivorship: Rationalizing your program costs
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|